GlassScriptPhysician profile
Nicole K Fitts
NPI 1356843684
$3,158.37
in general payments reported to CMS, 2019-2025
31 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.66 · 2022: $387 · 2023: $681 · 2024: $690 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,673 · Education: $62.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,673.41 |
| Education | $62.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $641.98 | 2022-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.89 | 2022-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $213.97 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $146.06 | 2023-2025 | Prolastin-C Liquid, Gamunex-C, Xembify |
| Pfizer INC. | $136.12 | 2022-2025 | |
| Glaxosmithkline, LLC. | $130.58 | 2022-2025 | Nucala |
| United Therapeutics Corporation | $128.36 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Merck Sharp & Dohme LLC | $121.58 | 2022-2025 | Zerbaxa, Winrevair |
| Csl Behring | $116.83 | 2023-2025 | Kcentra |
| Genentech USA, INC. | $113.67 | 2022-2025 | Xolair |
| Actelion Pharmaceuticals US, INC. | $109.78 | 2022-2025 | Uptravi, Opsumit |
| Jazz Pharmaceuticals INC. | $106.58 | 2023-2025 | |
| Amgen INC. | $105.33 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $83.95 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $80.61 | 2023-2025 | Sunosi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $75.65 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $74.98 | 2022-2025 | Acthar |
| Genzyme Corporation | $68.14 | 2025 | |
| Idorsia Pharmaceuticals US INC | $66.10 | 2023-2024 | Quviviq |
| Electromed, INC. | $53.21 | 2023-2025 | Smartvest |
| Insmed, INC. | $47.79 | 2025 | Arikayce |
| Novartis Pharmaceuticals Corporation | $47.44 | 2023-2024 | |
| Mylan Specialty L.P. | $47.15 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $43.89 | 2025 | Glassia |
| Ani Pharmaceuticals, INC. | $40.92 | 2022-2023 | Purified Cortrophin Gel |
| Medtronic, INC. | $34.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.66 | 2022-2023 | |
| Zoll Respicardia, INC. | $20.04 | 2023 | Remede System |
| Lilly USA, LLC | $17.29 | 2025 | Zepbound |
| Verona Pharma, INC. | $16.46 | 2025 | Ohtuvayre |
| Philips North America LLC | $14.70 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Fitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.